Evidence map›Paper›PMID 34063463›Full record

ArticleViruses2021

Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity.

Hengsheng Fang, Adam D Wegman, Kianna Ripich, Heather Friberg, Jeffrey R Currier, Stephen J Thomas, Timothy P Endy, Adam T Waickman

Open access · goldAbstract read
In one paragraph

Article in Viruses, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. COVID-19: Using high-throughput flow cytometry to dissect clinical heterogeneity.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2023
    Review
  6. Review
  7. Simultaneous analysis of antigen-specific B and T cells after SARS-CoV-2 infection and vaccination.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2022
    Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Hengsheng FangDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Adam D WegmanDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Kianna RipichInstitute for Global Health and Translational Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Heather FribergViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Jeffrey R CurrierViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Stephen J ThomasDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Timothy P EndyDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
Adam T WaickmanDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA.
SUNY Upstate Medical University · USWalter Reed Army Institute of Research · US

Funding

New York State NA
6 · The paper itself

Abstract

SARS-CoV-2 represents an unprecedented public health challenge. While the majority of SARS-CoV-2-infected individuals with mild-to-moderate COVID-19 resolve their infection with few complications, some individuals experience prolonged symptoms lasting for weeks after initial diagnosis. Persistent viral infections are commonly accompanied by immunologic dysregulation, but it is unclear if persistent COVID-19 impacts the development of virus-specific cellular immunity. To this end, we analyzed SARS-CoV-2-specific cellular immunity in convalescent COVID-19 patients who experienced eight days or fewer of COVID-19 symptoms or symptoms persisting for 18 days or more. We observed that persistent COVID-19 symptoms were not associated with the development of an overtly dysregulated cellular immune response. Furthermore, we observed that reactivity against the N protein from SARS-CoV-2 correlates with the amount of reactivity against the seasonal human coronaviruses 229E and NL63. These results provide insight into the processes that regulate the development of cellular immunity against SARS-CoV-2 and related human coronaviruses.

Indexed as

AdultAgedAged, 80 and overAntibodies, ViralCoronavirus 229E, HumanCOVID-19Cross ReactionsEpitopes, T-LymphocyteFemaleHumansImmunity, CellularMaleMiddle AgedNew YorkPost-Acute COVID-19 SyndromeSARS-CoV-2Antibodies, ViralEpitopes, T-Lymphocytecellular immunityCOVID-19SARS-CoV-2symptom durationT cells

Identifiers

PMID34063463
PMCPMC8155927
OpenAlexW3159992362

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.